Evidence map›Paper›PMID 34756322›Full record

ArticleReumatologia clinica2021

Why choose cyclosporin A as first-line therapy in COVID-19 pneumonia.

Olga Sanchez-Pernaute, Fredeswinda I Romero-Bueno, Albert Selva-O'Callaghan

Abstract readLetter
In one paragraph

Article in Reumatologia clinica, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Olga Sanchez-PernauteRheumatology Division, Jiménez Díaz Foundation University Hospital and Health Research Institute, Universidad Autónoma de Madrid, Madrid, Spain. Electronic address: osanchez@fjd.es.
Fredeswinda I Romero-BuenoRheumatology Division, Jiménez Díaz Foundation University Hospital and Health Research Institute, Universidad Autónoma de Madrid, Madrid, Spain.
Albert Selva-O'CallaghanDepartment of Internal Medicine, Hospital Universitari Val d'Hebron, Universitat Autonoma de Barcelona, Barcelona, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

COVID-19 Drug TreatmentAntibodies, Monoclonal, HumanizedCyclosporineCytokine Release SyndromeHumansImmunosuppressive AgentsSARS-CoV-2Antibodies, Monoclonal, HumanizedCyclosporineImmunosuppressive Agentstocilizumab

Identifiers

PMID34756322
PMCPMC8555974

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.